EX-2 4 ex-2.txt Financial Statements for the 14 months ended 31 May 2002 for CLL Pharma S.A. The Financial Statements have been prepared in US GAAP from the original French accounts, prepared in Euro's, which were audited by the Ernst and Young Office in Nice, France. CLL Pharma S.A. Contents of the Financial Statements for the 14 months ended 31 May 2002 Page Balance Sheet 1 Profit and Loss Account 2 Notes to the Financial Statements 3 to 7 CLL Pharma S.A. Consolidated Balance Sheet As at 31 May 2002

2 CLL Pharma S.A. Notes to the Financial Statements for the 14 months ended 31 May 2002 1. ACCOUNTING POLICIES Accounting convention The financial statements have been prepared in US GAAP under the historical cost convention and the basis of presentation is :- Turnover Sales of finished goods are accounted for on the date the goods are delivered. Royalties receivable on licences and research and development are spread over the term of the contracts. Other royalties receivable are accounted for on a receipts basis.

Stocks Stock of raw materials is valued at cost using the FIFO method. Work in progress is valued at cost. A provision for depreciation is made when the cost of the stock of raw materials is higher than the net realisable value. Investments Investments are valued at cost. Foreign Currencies Assets and liabilities in foreign currencies are translated at the rates of exchange ruling at the date of the Balance Sheet. Transactions in foreign currencies are translated into dollars at the average rate of exchange during the period that the accounts cover. 3

6 CLL Pharma S.A. Notes to the Financial Statements for the 14 months ended 31 May 2002 8. COMMON STOCK Authorised, alloted, issued and fully paid. Number Class Nominal 31-May-02 31-Mar-01 value US$ US$ 74,297 Ordinary 54 EURO 3,755,897 3,450,820 870 new shares at 54 Euro per share issued during the period. 7

NEURO BIOSCIENCE INC 8-K/A